Overview

Equivalence Study to Compare Two Strengths of Creon in China

Status:
Recruiting
Trial end date:
2021-08-01
Target enrollment:
Participant gender:
Summary
This will be an open-label, randomized, multicenter, cross-over study in 60 subjects with PEI delivering data of 60 subjects for Pancreatin Enteric-Coated Capsules 25000 and of 60 subjects for Pancreatin Enteric-Coated Capsules 10000. The study will be conducted in up to 10 sites in China.
Phase:
Phase 3
Details
Lead Sponsor:
Abbott
Treatments:
Pancreatin
Pancrelipase